Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such
as irinotecan, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Giving bevacizumab together with irinotecan may
kill more tumors cells.
PURPOSE: This phase II trial is studying the side effects of bevacizumab and how well giving
bevacizumab together with irinotecan works in treating patients with recurrent or refractory
gliomas.